Vaccines prevent infectious disease largely by inducing protective neutralizing antibodies
against vulnerable epitopes. Several major pathogens have resisted traditional vaccine …

Induction of broadly neutralizing antibodies (bnAbs) is a major HIV vaccine goal. Germline-targeting
immunogens aim to initiate bnAb induction by activating bnAb germline precursor B …

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env). Poor …

Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env)
trimer are the most common bnAbs induced during infection, making them promising …

Germinal centres are the engines of antibody evolution. Here, using human immunodeficiency
virus (HIV) Env protein immunogen priming in rhesus monkeys followed by a long period …

A vaccine that elicits broadly neutralizing antibodies (bNAbs) against HIV-1 is likely to be
protective, but this has not been achieved. To explore immunization regimens that might elicit …

Induction of broadly neutralizing antibodies (bnAbs) is a primary goal of HIV vaccine
development. VRC01-class bnAbs are important vaccine leads because their precursor B cells …

Vaccines generate high-affinity antibodies by recruiting antigen-specific B cells to germinal
centers (GCs), but the mechanisms governing the recruitment to GCs on secondary …

HIV-1 envelope glycoprotein (Env) is the sole target for broadly neutralizing antibodies (bnAbs)
and the focus for design of an antibody-based HIV vaccine. The Env trimer is covered by …

INTRODUCTION HIV newly infects 1.8 million people each year, making development of an
HIV vaccine a global health priority. Nearly all licensed vaccines protect by inducing …